MAP2K7 and lung carcinoma: Recently, Lee et al. reported synergistic therapeutic effects of combined HSP90 and MEK inhibitors at sub-therapeutic dosages, with potent therapeutic results demonstrated in the treatment of Raf/MEK/ERK signaling pathway inhibitor resisted lung cancer with the KRAS-mutant [31].